NASDAQ:IPHA Innate Pharma Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Innate Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.86 +0.10 (+2.66 %) (As of 09/25/2020 12:00 AM ET) Add Compare Share Today's Range$3.65Now: $3.87▼$3.8750-Day Range$3.77MA: $5.53▼$6.5552-Week Range$3.30Now: $3.87▼$8.24Volume6,452 shsAverage Volume19,141 shsMarket Capitalization$295.84 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartCompetitorsInstitutional OwnershipHeadlinesShort InterestSocial Media Innate Pharma S.A., a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. The company offers IPH4102, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for cutaneous T-cell lymphomas; Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat various cancer indications and tumors; and IPH5401, a therapeutic antibody that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils. It also provides IPH5201, an anti-CD39 antibody and IPH5301, an anti-CD73 antibody, which is in pre-clinical stage for the treatment of immuno-oncology. In addition, the company offers IPH61, a bispecific NK cell engager that is used to create novel molecular formats to kill tumor cells through NKp46. Further, it provides Lumoxiti, a commercial-stage oncology product for treating hairy cell leukemia. Innate Pharma S.A. has licensing agreements with AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi; and a clinical trial collaboration with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingInnate Pharma has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, Innate Pharma has a forecasted upside of 81.1% from its current price of $3.87.Amount of Analyst CoverageInnate Pharma has only been the subject of 2 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesInnate Pharma has received 20 “outperform” votes. (Add your “outperform” vote.)Underperform VotesInnate Pharma has received 20 “underperform” votes. (Add your “underperform” vote.)Community SentimentInnate Pharma has received 50.00% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Innate Pharma and other stocks. Vote “Outperform” if you believe IPHA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IPHA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldInnate Pharma does not currently pay a dividend.Dividend GrowthInnate Pharma does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Innate Pharma insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 3.79% of the stock of Innate Pharma is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Innate Pharma are expected to decrease in the coming year, from ($0.14) to ($0.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Innate Pharma is -11.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Innate Pharma is -11.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInnate Pharma has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.17 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IPHA Previous Symbol CUSIPN/A CIKN/A Webwww.innate-pharma.com Phone33-4-30-30-30-30Debt Debt-to-Equity Ratio0.08 Current Ratio1.99 Quick Ratio1.95Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$96.12 million Price / Sales3.08 Cash FlowN/A Price / Cash FlowN/A Book Value$3.18 per share Price / Book1.22Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees200 Outstanding Shares76,543,000Market Cap$295.84 million Next Earnings DateN/A OptionableNot Optionable $3.86 +0.10 (+2.66 %) (As of 09/25/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive IPHA News and Ratings via Email Sign-up to receive the latest news and ratings for IPHA and its competitors with MarketBeat's FREE daily newsletter. Innate Pharma (NASDAQ:IPHA) Frequently Asked Questions How has Innate Pharma's stock price been impacted by COVID-19 (Coronavirus)? Innate Pharma's stock was trading at $6.30 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, IPHA shares have decreased by 38.7% and is now trading at $3.8650. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Innate Pharma? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innate Pharma in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Innate Pharma. What price target have analysts set for IPHA? 3 analysts have issued 1 year price objectives for Innate Pharma's shares. Their forecasts range from $7.00 to $7.00. On average, they expect Innate Pharma's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 81.1% from the stock's current price. View analysts' price targets for Innate Pharma. Are investors shorting Innate Pharma? Innate Pharma saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 29,300 shares, an increase of 70.3% from the August 31st total of 17,200 shares. Based on an average trading volume of 10,000 shares, the short-interest ratio is presently 2.9 days. View Innate Pharma's Short Interest. Who are some of Innate Pharma's key competitors? Some companies that are related to Innate Pharma include Compugen (CGEN), I-Mab (BDTX), Regenxbio (RGNX), Adaptimmune Therapeutics (ADAP), Translate Bio (TBIO), Atara Biotherapeutics (ATRA), Alector (ALEC), Adverum Biotechnologies (ADVM), Replimune Group (REPL), Vericel (VCEL), Krystal Biotech (KRYS), Vaxart (VXRT), Nantkwest (NK), Cellectis (CLLS) and Agenus (AGEN). View all competitors. What other stocks do shareholders of Innate Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Innate Pharma investors own include Cidara Therapeutics (CDTX), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (vbiv), Gilead Sciences (GILD), Ocular Therapeutix (OCUL), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), (MRNA) and Pluristem Therapeutics (PSTI). Who are Innate Pharma's key executives? Innate Pharma's management team includes the following people: Dr. Hervé Brailly, Co-Founder & Chairman of Supervisory Board (Age 58)Dr. Mondher Mahjoubi, Chairman of Exec. Board & CEO (Age 61)Mr. Yannis Morel, Exec. VP of Product Portfolio Strategy & Bus. Devel. and Member of Exec. Board (Age 46)Ms. Laure-Hélène Mercier M.B.A., M.Sc., MSc, MBA, Exec. VP, CFO & Member of Exec. Board (Age 41)Mr. Eric Vivier D.V.M., Ph.D., Sr. VP & Chief Scientific Officer (Age 55) When did Innate Pharma IPO? (IPHA) raised $80 million in an initial public offering (IPO) on Thursday, October 17th 2019. The company issued 10,700,000 shares at a price of $7.50 per share. Citigroup, SVB Leerink and Evercore ISI served as the underwriters for the IPO. What is Innate Pharma's stock symbol? Innate Pharma trades on the NASDAQ under the ticker symbol "IPHA." How do I buy shares of Innate Pharma? Shares of IPHA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Innate Pharma's stock price today? One share of IPHA stock can currently be purchased for approximately $3.87. How big of a company is Innate Pharma? Innate Pharma has a market capitalization of $295.84 million and generates $96.12 million in revenue each year. The company earns $-23,250,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis. Innate Pharma employs 200 workers across the globe. What is Innate Pharma's official website? The official website for Innate Pharma is www.innate-pharma.com. How can I contact Innate Pharma? Innate Pharma's mailing address is 117 AVENUE DE LUMINY BP 30191, MARSEILLE I0, 13009. The company can be reached via phone at 33-4-30-30-30-30 or via email at [email protected] This page was last updated on 9/26/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
